Menu
Back to Journals » Biologics: Targets and Therapy » Volume 12
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (502)
- Volume 18, 2024 (6)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 12, 2018
The role of microfluidics in protein formulations with pre-programmed functional characteristics
Meng H, Deng S, You Y, Chan HF
Biologics: Targets and Therapy 2018, 12:191-197
Published Date: 3 December 2018
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
Wen M, Xia J, Sun Y, Wang X, Fu X, Zhang Y, Zhang Z, Zhou Y, Li X
Biologics: Targets and Therapy 2018, 12:183-190
Published Date: 30 November 2018
Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results
Nozaki Y, Nagare Y, Ashida C, Tomita D, Okada A, Inoue A, Kinoshita K, Funauchi M, Matsumura I
Biologics: Targets and Therapy 2018, 12:171-182
Published Date: 27 November 2018
Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product
Singh SK, Pokalwar S, Bose S, Gupta S, Almal S, Ranbhor RS
Biologics: Targets and Therapy 2018, 12:159-170
Published Date: 23 November 2018
Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
Degli Esposti L, Perrone V, Sangiorgi D, Buda S, Andretta M, Rossini M, Girolomoni G
Biologics: Targets and Therapy 2018, 12:151-158
Published Date: 12 November 2018
The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
Heslinga SC, Konings TC, van der Horst-Bruinsma IE, Kamp O, van Halm VP, de Bruin-Bon HACM, Peters MJ, Nurmohamed MT
Biologics: Targets and Therapy 2018, 12:143-149
Published Date: 8 November 2018
Two decades with omalizumab: what we still have to learn
Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E
Biologics: Targets and Therapy 2018, 12:135-142
Published Date: 26 October 2018
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Simsek I
Biologics: Targets and Therapy 2018, 12:127-134
Published Date: 25 October 2018
Designing of CD8+ and CD8+-overlapped CD4+ epitope vaccine by targeting late and early proteins of human papillomavirus
Kaliamurthi S, Selvaraj G, Kaushik AC, Gu KR, Wei DQ
Biologics: Targets and Therapy 2018, 12:107-125
Published Date: 2 October 2018
A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population
Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Mutlu EA, Simsek I
Biologics: Targets and Therapy 2018, 12:97-106
Published Date: 2 October 2018
Focus on biosimilar etanercept – bioequivalence and interchangeability
Cantini F, Benucci M
Biologics: Targets and Therapy 2018, 12:87-95
Published Date: 30 August 2018
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
Pan YH, Jiao L, Lin CY, Lu CH, Li L, Chen HY, Wang YB, He Y
Biologics: Targets and Therapy 2018, 12:75-86
Published Date: 20 August 2018
Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
Matsumoto S, Mashima H
Biologics: Targets and Therapy 2018, 12:69-73
Published Date: 19 July 2018
The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation
Hakimian S, Popov Y, Rupawala AH, Salomon-Escoto K, Hatch S, Pellish R
Biologics: Targets and Therapy 2018, 12:61-67
Published Date: 27 February 2018
New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
Lundstrom K
Biologics: Targets and Therapy 2018, 12:43-60
Published Date: 9 February 2018
Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F
Biologics: Targets and Therapy 2018, 12:37-41
Published Date: 31 January 2018
Analytical characterization of recombinant hCG and comparative studies with reference product
Thennati R, Singh SK, Nage N, Patel Y, Bose SK, Burade V, Ranbhor RS
Biologics: Targets and Therapy 2018, 12:23-35
Published Date: 30 January 2018
Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
Navalkele BD, Chopra T
Biologics: Targets and Therapy 2018, 12:11-21
Published Date: 18 January 2018
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
Chen YH, Carvalho HMS, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS
Biologics: Targets and Therapy 2018, 12:1-9
Published Date: 12 January 2018